LPOXY Therapeutics

Executive Summary

LPOXY Therapeutics is a Cambridge-based biopharmaceutical company pioneering a novel approach to prevent antibiotic-induced Clostridioides difficile colitis using its proprietary SIDIPREV™ technology. SIDIPREV is an orally administered, metered-dose capsule designed to deliver oxygen directly to the bowel, thereby disrupting the anaerobic environment that C. difficile requires to proliferate. The lead indication addresses a significant unmet need in healthcare-associated infections, which affect hundreds of thousands of patients annually and carry high morbidity and mortality. Additionally, the platform is being explored for maintaining remission in inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. Founded in 2021, the company is still in the early stages of development with no disclosed funding rounds or valuation, reflecting its nascent position. The technology's novelty and potential to address both infectious and chronic inflammatory conditions provide a compelling rationale for further development, though clinical validation is pending.

Upcoming Catalysts (preview)

• TBDIND Filing or Phase 1 Trial Initiation for SIDIPREV in C. difficile Prevention60% success
• TBDPreclinical Proof-of-Concept Data Publication or Presentation70% success
• TBDStrategic Partnership or Grant Award for IBD Indication50% success